<DOC>
	<DOCNO>NCT01598896</DOCNO>
	<brief_summary>Cannabis use disorder important public health problem United States , effective pharmacotherapies available treat disorder . People schizophrenia likely healthy people abuse cannabis . Cannabis use may worsen clinical outcome group , make identification pharmacotherapy treat cannabis dependence schizophrenia important . The investigator intend test combination dronabinol , cannabinoid agonist , α2-adrenergic agonist clonidine , cannabis dependence subject schizophrenia . The combination dronabinol clonidine may alleviate cannabis withdrawal symptom allow treatment-seeking outpatient benefit medical management ( MM ) session try stop use cannabis . The investigator propose assess relationship dronabinol clonidine , add MM , cannabis use pattern cannabis-dependent patient schizophrenia . Hypothesis : The investigator predict combination pharmacotherapy dronabinol clonidine significantly reduce cannabis use compare receive placebo .</brief_summary>
	<brief_title>Combination Dronabinol Clonidine Cannabis Dependence Patients With Schizophrenia</brief_title>
	<detailed_description>Subjects receive either combination dronabinol clonidine placebo addition medical management ( MM ) 10-week treatment period . Following treatment completion , subject follow-up visit 14 week treatment initiation . This pilot study evaluate feasibility combination dronabinol clonidine cannabis dependence establish effect size large trial . Cannabis use disorder highly prevalent United States rise among high school senior , make identification efficacious treatment cannabis dependence critical clinical public health significance . Schizophrenia overrepresented among cannabis dependence . At completion study , investigator hope improve understanding relationship pharmacotherapy combination dronabinol clondine cannabis use .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>1 . Age range 1845 year 2 . DSMIV diagnosis cannabis dependence , base Structured Clinical Interview DSMIV ( SCID ) 3 . DSMIV diagnosis schizophrenia schizoaffective disorder , base Structured Clinical Interview DSMIV ( SCID ) 4. express desire quit cannabis use within next 30 day 5. used cannabis ≥20 day within past 30 day ( i.e. , average ≥5 day per week ) 6. identify cannabis primary drug abuse ; 6 ) stable antipsychotic medication ≥1 month 7. woman childbearing age , negative pregnancy test screening agreement use adequate contraception prevent pregnancy monthly pregnancy test 8. consent u communicate prescribe clinician one exist 9. furnish name 2 locator , would assist study staff locate study period 10. live close enough McLean Hospital attend study visit 11. plan stay Boston area next 3 month 12. willing able sign inform consent . 1 . Current diagnosis drug alcohol dependence ( exclude nicotine ) 2. significant cardiac disease indicate history suspect abnormal ECG history cardiac symptoms 3 . Positive Negative Syndrome Scale ( PANSS ) subscale positive symptom psychosis item &gt; 3 ( moderate ) baseline evaluation 4. current medical condition could prevent regular study attendance 5. liver function test &gt; 3 time upper limit normal range 6. history seizure disorder history head trauma CNS insult could predispose subject seizure 7. take clozapine 8. current suicidal risk 9. bradycardia less equal 50 bpm , supine blood pressure less equal 100/65 , seat blood pressure less equal 90/60 , orthostatic change &gt; 20 systolic &gt; 10 diastolic standing , screen predose assessment , symptom attributable low BP ( i.e . lightheadedness dizziness stand ) 10. mental retardation organic mental disorder 11. currently residential treatment set substance use monitor restrict , since restrict access drug could represent important confound variable 12. pregnant , nursing , , woman childbearing potential , use form birth control judge investigator effective 13. concomitant treatment opioid analgesic , sedative hypnotic , know CNS depressant 14. know hypersensitivity cannabinoids sesame oil clonidine 15. disease gastrointestinal system , liver , kidney may impede metabolism excretion dronabinol 16. inability read write English would hinder ability follow study procedure 17. history seizure family history seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cannabis Dependence</keyword>
	<keyword>Marijuana Dependence</keyword>
	<keyword>Cannabis Use Disorders</keyword>
	<keyword>Cannabis Withdrawal</keyword>
	<keyword>Dronabinol</keyword>
	<keyword>Clonidine</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>